Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2016.8655PMID 27380342
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chorea associated with Huntington's disease: To treat or not to treat?

  2014cited by this paper
• Using deuterium in drug discovery: leaving the label in the drug.

  2014cited by this paper
• Natural history of Huntington disease.

  2013cited by this paper
• Analysis of CYP2D6 genotype and response to tetrabenazine

  2013cited by this paper
• Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington’s and Other Diseases

  2013cited by this paper
• Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

  2013cited by this paper
• Kinetic deuterium isotope effects in cytochrome P450 oxidation reactions.

  2013cited by this paper
• Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease

  2012cited by this paper
• The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.

  2011cited by this paper
• Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders

  2011cited by this paper
• Advances in the Pharmacological Management of Huntington’s Disease

  2010cited by this paper
• Global Rating of Change Scales: A Review of Strengths and Weaknesses and Considerations for Design

  2009cited by this paper
• Practice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

  2007cited by this paper
• Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease

  2007cited by this paper
• Tetrabenazine as antichorea therapy in Huntington disease

  2006cited by this paper
• The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment

  2005cited by this paper
• Assessing the clinical significance of change scores recorded on subjective outcome measures.

  2004cited by this paper
• Pharmacological uses and perspectives of heavy water and deuterated compounds.

  1999cited by this paper
• Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study.

  1997cited by this paper
• Unified Huntington's disease rating scale: reliability and consistency

  1996cited by this paper
• Unified Huntington's disease rating scale: Reliability and consistency

  1996cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• The MOS 36-Item Short-Form Health Survey (SF-36)

  1992cited by this paper
• The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

  1992cited by this paper
• A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

  1991cited by this paper
• Measuring balance in the elderly: preliminary development of an instrument

  1989cited by this paper
• A Rating Scale for Drug-Induced Akathisia

  1989cited by this paper
• Huntington's disease in Venezuela

  1986cited by this paper
• Deuterium isotope effects in studies of drug metabolism

  1984cited by this paper
• The Hospital Anxiety and Depression Scale

  1983cited by this paper

• The therapeutic potential of laquinimod for Huntington's disease: A systematic review of preclinical and clinical studies.

  2026cites this paper
• Efficacy and Safety of VMAT2 Inhibitors in the Treatment of Huntington Disease: A Meta-Analysis of Randomized Clinical Trials.

  2026cites this paper
• Safety and efficacy of VMAT2 inhibitors in Huntington Disease: A systematic review.

  2026cites this paper
• Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease

  2025cites this paper
• Examination of Anti-Inflammatory Effects After Propionate Supplementation in the R6/2 Mouse Model of Huntington’s Disease

  2025cites this paper
• Huntington Disease and Chorea.

  2025cites this paper
• Pridopidine in early-stage manifest Huntington’s disease: a phase 3 trial

  2025cites this paper
• How Early Does Anosognosia Begin in Huntington's Disease?

  2025cites this paper
• The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease

  2025cites this paper
• Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease

  2025cites this paper
• Phase II trial of intravenous human dental pulp stem cell therapy for Huntington’s disease: a randomized, double-blind, placebo-controlled study

  2025cites this paper
• Comparison of tetrabenazine, tiapride and olanzapine in Huntington's disease: a one-year French randomized multicenter study (Neuro-HD).

  2025cites this paper
• Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington’s Disease: Data from Enroll-HD

  2025cites this paper
• Nickel-Catalyzed Deuteration of Primary, Secondary, and Tertiary Silanes: Scope and Mechanistic Insights

  2025cites this paper
• Deutetrabenazine treatment outcomes with doses above U.S. Food and Drug Administration maximum approved doses in Huntington's disease chorea: A dual-site analysis

  2025cites this paper
• Update on the Symptomatic Treatment of Huntington’s Disease: From Pathophysiology to Clinical Practice

  2025cites this paper
• Efficacy and Safety of VMAT-2 Inhibitors and Dopamine Stabilizers for Huntington’s Chorea: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis

  2025cites this paper
• Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database

  2025cites this paper
• Neurotransmitters in Neural Circuits and Neurological Diseases.

  2025cites this paper
• Vesicular monoamine transport inhibitors: current uses and future directions.

  2025cites this paper
• Antidopaminergic medications in Huntington's disease

  2025cites this paper
• Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington’s disease chorea based on network meta-analysis

  2025cites this paper
• Baicalein-mediated regulation of Nrf2/ARE, NFĸB, and MAPK signaling in Huntington’s disease: a promising strategy against neuroinflammation and neurodegeneration

  2025cites this paper
• Emerging therapeutic strategies in glioblastsoma: drug repurposing, mechanisms of resistance, precision medicine, and technological innovations

  2025cites this paper
• Therapeutic potential of mesenchymal stem cells in neurodegenerative diseases

  2025cites this paper
• Evidence-Based Review on Symptomatic Management of Huntington’s Disease

  2024cites this paper
• Theory of Mind in Huntington’s Disease: A Systematic Review of 20 Years of Research

  2024cites this paper
• Factors Influencing Discharges to Hospice for Patients With Late-Stage Huntington’s Disease

  2024cites this paper
• Saccades, pupil response and blink abnormalities in Huntington's disease patients during free viewing.

  2024cites this paper
• Dissemination of VMAT-2 Inhibitors

  2024cites this paper
• Estimation of Gait Parameters in Huntington’s Disease Using Wearable Sensors in the Clinic and Free-living Conditions

  2024cites this paper
• Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease

  2024cites this paper
• Symptomatic Treatment of Extrapyramidal Hyperkinetic Movement Disorders

  2024cites this paper
• Potential molecular mechanism of exercise reversing insulin resistance and improving neurodegenerative diseases

  2024cites this paper
• Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.

  2024cites this paper
• Valbenazine for the treatment of chorea associated with Huntington’s disease

  2024cites this paper
• Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington’s disease

  2024cites this paper
• Clinical experience and treatment considerations with vesicular monoamine transport 2 inhibitors

  2024cites this paper
• Synthesis of deuteriodifluoromethylthiolated isocoumarins-1-imines and isocoumarins enabled by multi-component reagents system (MCRS).

  2024cites this paper
• Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease

  2024cites this paper
• Influence of anosognosia on patient-reported outcomes for psychiatric symptoms and quality of life in Huntington's disease.

  2024cites this paper
• Drug inhibition and substrate alternating flipping mechanisms of human VMAT2

  2024cites this paper
• Unraveling the Puzzle of Therapeutic Peptides: A Promising Frontier in Huntington's Disease Treatment.

  2024cites this paper
• Room-Temperature Copper-Catalyzed Etherification of Aryl Bromides.

  2024cites this paper
• Medication Use and Treatment Indications in Huntington's Disease; Analyses from a Large Cohort

  2024cites this paper
• The Impact of Aging on Neurological Diseases in the Elderly: Molecular Mechanisms and Therapeutic Perspectives

  2024cites this paper
• A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady State

  2024cites this paper
• Translational Approach Using Advanced Therapy Medicinal Products for Huntington's Disease.

  2024cites this paper
• Exploring the Role of Deutetrabenazine in the Treatment of Chorea Linked with Huntington's Disease.

  2024cites this paper
• First-in-human study of D6-[18F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [18F]FP-(+)-DTBZ (AV-133)

  2024cites this paper
• What Huntington’s Disease Patients Say About Their Illness: An Online Direct-to-Participant Pilot Study

  2024cites this paper
• From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research

  2023cites this paper
• Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension Study

  2023cites this paper
• Real‐World Experience With Deutetrabenazine for Huntington Disease Chorea

  2023cites this paper
• Sleep Dysfunction in Huntington’s Disease: Impacts of Current Medications and Prospects for Treatment

  2023cites this paper
• Valbenazine as treatment for Huntington's disease chorea.

  2023cites this paper
• Deuterium in drug discovery: progress, opportunities and challenges

  2023cites this paper
• Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

  2023cites this paper
• Pyroptosis in neurodegenerative diseases: from bench to bedside

  2023cites this paper
• Deuterated driven new chemical entities: An optimistic way to improve therapeutic efficacy.

  2023cites this paper
• The optimal pre-post allocation for randomized clinical trials

  2023cites this paper
• The Emerging Landscape of Natural Small-molecule Therapeutics for Huntington’s Disease

  2023cites this paper
• The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ

  2023cites this paper
• Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose

  2023cites this paper
• Artificial intelligence in healthcare: a mastery

  2023cites this paper
• Small molecules to perform big roles: The search for Parkinson's and Huntington's disease therapeutics

  2023cites this paper
• Thermal Adsorption Spectroscopy of Hydrogen Isotopes from CHA-Type Zeolites

  2023cites this paper
• Analysis of orphan designation status for FDA approved drugs, and case studies in oncology, neuroscience and metabolic diseases.

  2023cites this paper
• Treatment of tardive dystonia: A review

  2023cites this paper
• Selective Deuteration Improves the Affinity of Adenosine A2A Receptor Ligands: A Computational Case Study with Istradefylline and Caffeine

  2023cites this paper
• Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society)

  2023cites this paper
• Real-world experience with Deutetrabenazine management in patients with Huntington’s disease using video-based telemedicine

  2023cites this paper
• Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington’s Disease and Tardive Dyskinesia

  2023influential citation
• Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes

  2023cites this paper
• Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.

  2023cites this paper
• Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia

  2023cites this paper
• Therapeutic Strategies in Huntington’s Disease: From Genetic Defect to Gene Therapy

  2022cites this paper
• Huntington's Disease: A Clinical Review

  2022cites this paper
• Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc Analysis

  2022cites this paper
• deutetrabenazine for the treatment of chorea associated with Huntington's disease.

  2022cites this paper
• Current and Possible Future Therapeutic Options for Huntington’s Disease

  2022cites this paper
• How “Neuronal” Are Human Skin Mast Cells?

  2022cites this paper
• An MDS Evidence‐Based Review on Treatments for Huntington's Disease

  2022influential citation
• Meta‐Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders

  2022cites this paper
• A novel rhesus macaque model of Huntington’s disease recapitulates key neuropathological changes along with motor and cognitive decline

  2022cites this paper
• A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease

  2022cites this paper
• The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.

  2022cites this paper
• Chorea

  2022cites this paper
• The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study

  2022cites this paper
• Clinical Application and Synthesis Methods of Deuterated Drugs.

  2022cites this paper
• Nrf2 Pathway in Huntington’s Disease (HD): What Is Its Role?

  2022cites this paper
• The tardive syndromes

  2021cites this paper
• State-of-the-art pharmacological approaches to reduce chorea in Huntington’s disease

  2021cites this paper
• Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders

  2021cites this paper
• Huntington’s Disease: New Frontiers in Therapeutics

  2021cites this paper
• Approach to the Patient with Gait Disturbance.

  2021cites this paper
• Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome

  2021cites this paper
• Management of Motor Symptoms in Dementia Disorders

  2021cites this paper
• New Avenues for the Treatment of Huntington’s Disease

  2021cites this paper
• ISSN: 2595-6825

  2021cites this paper